The Spectacle Of Trump: Tweets, Insults And A Year Pharma Won't Forget
Executive Summary
From "getting away with murder" to "rip-off drug prices," pharma had its share of face-offs with President Trump in 2017. In the end, industry appears to have fared well under the pro-business leader, with industry insider Alex Azar now heading HHS and corporate tax reform a new year treat for industry.
You may also be interested in...
BIO Chair Ted Love On Drug Pricing And Political Pressure
Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.
BIO Chair Ted Love On Drug Pricing And Political Pressure
Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.
A New Year And New Drug Price Increases
It's the time of year when many drug companies raise prices on mature medicines, and Allergan is one that raised prices on several drugs in its portfolio by 9.5%, just barely keeping to its social contract with patients.